2. Academic Validation
  3. Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK

Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK

  • Sci Rep. 2021 Jul 1;11(1):13700. doi: 10.1038/s41598-021-93156-1.
Marine Angé 1 2,  Julien De Poortere 1,  Audrey Ginion 1,  Sylvain Battault 1,  Mélanie Dechamps 1 3,  Giulio G Muccioli 4,  Martin Roumain 4,  Johann Morelle 5 6,  Sébastien Druart 5 6,  Thomas Mathivet 7,  Luc Bertrand 1,  Diego Castanares-Zapatero 1 3,  Sandrine Horman  # 1,  Christophe Beauloye  # 8 9
Affiliations

Affiliations

  • 1 Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 55, Avenue Hippocrate B1.55.03.1322, 1200, Brussels, Belgium.
  • 2 Division of Pediatrics, Cliniques Universitaires Saint Luc, 1200, Brussels, Belgium.
  • 3 Division of Intensive Care, Cliniques Universitaires Saint Luc, 1200, Brussels, Belgium.
  • 4 Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), 1200, Brussels, Belgium.
  • 5 Division of Nephrology, Cliniques Universitaires Saint-Luc, 1200, Brussels, Belgium.
  • 6 Pôle Nephrologie (NEFR), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 1200, Brussels, Belgium.
  • 7 Inserm U970, Paris Cardiovacular Research Center, 75015, Paris, France.
  • 8 Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), 55, Avenue Hippocrate B1.55.03.1322, 1200, Brussels, Belgium. christophe.beauloye@uclouvain.be.
  • 9 Division of Cardiology, Cliniques Universitaires Saint-Luc, 1200, Brussels, Belgium. christophe.beauloye@uclouvain.be.
  • # Contributed equally.
PMID: 34211080 DOI: 10.1038/s41598-021-93156-1
Abstract

Sepsis capillary leak syndrome (SCLS) is an independent prognostic factor for poor sepsis outcome. We previously demonstrated that α1AMP-activated protein kinase (α1AMPK) prevents sepsis-induced vascular hyperpermeability by mechanisms involving VE-cadherin (VE-Cad) stabilization and activation of p38 mitogen activated protein kinase/heat shock protein of 27 kDa (p38MAPK/HSP27) pathway. Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, has recently been proven to activate AMPK in endothelial cells. Therefore, we hypothesized that canagliflozin could be of therapeutic potential in patients suffering from SCLS. We herein report that canagliflozin, used at clinically relevant concentrations, counteracts lipopolysaccharide-induced vascular hyperpermeability and albumin leakage in wild-type, but not in endothelial-specific α1AMPK-knockout mice. In vitro, canagliflozin was demonstrated to activate α1AMPK/p38MAPK/HSP27 pathway and to preserve VE-Cad's integrity in human endothelial cells exposed to human septic plasma. In conclusion, our data demonstrate that canagliflozin protects against SCLS via an α1AMPK-dependent pathway, and lead us to consider novel therapeutic perspectives for this drug in SCLS.

Figures
Products